3 Houston innovators to know this week

Who's who

Three Houston innovators to know this week include Kim Raath of Topl, Gaurav Khandelwal of ChaiOne, and Nobel Prize winner Jim Allison. Courtesy photos

This week's Houston innovators to know include a blockchain expert with insight on how COVID-19 is affecting supply chain, a Houston tech leader with a logistics software solution, and a streamable story on cancer treatment innovation.

Kim Raath, CEO and co-founder of Topl

Photo courtesy of Topl

Amid the negativity the COVID-19 news, one Houston startup had an exciting announcement. It reworked its C-suite and Kim Raath, who just finished Ph.D in statistics and a Master's in economics at Rice University, has transitioned into the CEO role. Raath and her co-founders, James Aman and Chris Georgen, recently convened to re-envision the company's next phase.

"It was definitely a cool experience for us as founders to go through together, but I'm glad that all three of us came out of this excited about what we're doing moving forward," says Raath. Read more.

Gaurav Khandelwal, CEO and founder of ChaiOne

Photo courtesy of ChaiOne

Houston tech company ChaiOne recently announced the soft launch of Velostics, the "slack" for logistics that solve wait times and cash flow challenges in the supply chain and logistics industry. The digital logistics platform is set to aid the struggling supply chain as surging demands stretch suppliers, offering their platform free for 60 days.

"At ChaiOne we have a history of helping Houstonians whenever disaster strikes," says CEO and founder, Gaurav Khandelwal. "We created a disaster connect app during Hurricane Harvey for free that connected people with the resources they need. Velostics by pure happenstance happened to be ready for situations like [the coronavirus] when there's a lot of parties that need to collaborate." Read more.

James Allison, chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center

Jim Allison MD Anderson

Photo courtesy of MD Anderson Cancer Center

In a time when our health care heroes are serving on the front lines of the coronavirus, it's a great reminder of the work they all do round — from the research labs and academic institutions to the patient rooms. Jim Allison, a researcher in immunotherapy for MD Anderson Cancer Center recently took home the Nobel Prize for his work. He went on to be the subject of a documentary that premiered at SXSW last year, and that film will be coming to a TV near you.

Jim Allison: Breakthrough premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App. Read more.
Houston's Nobel Prize winner, Jim Allison, is the star of Breakthrough, which premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App. Photo via SXSW.com

Documentary featuring Houston Nobel Prize winner to air on PBS

to-watch list

Not all heroes wear capes. In fact, our current coronavirus heroes are donning face masks as they save lives. One local health care hero has a different disease as his enemy, and you'll soon be able to stream his story.

Dr. James "Jim" Allison won the 2018 Nobel Prize in Physiology or Medicine for his work in battling cancer by treating the immune system — rather than the tumor. Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center, has quietly and often, singularly, waged war with cancer utilizing this unique approach.

The soft-spoken trailblazer is the subject of an award-winning documentary, Jim Allison: Breakthrough, which will air on PBS and its streaming channels on Monday, April 27 at 9 pm (check local listings for channel information). Lauded as "the most cheering film of the year" by the Washington Post, the film follows Allison's personal journey to defeat cancer, inspired and driven by the disease killed his mother.

Breakthrough is narrated by Woody Harrelson and features music by Willie Nelson, adding a distinct hint of Texana. (The film was a star at 2019's South by Southwest film festival.) The documentary charts Alice, Texas native as he enrolls at the University of Texas, Austin and ultimately, cultivates an interest in T cells and the immune system — and begins to frequent Austin's legendary music scene. Fascinated by the immune system's power to protect the body from disease, Allison's research soon focuses on how it can be used to treat cancer.

Viewers will find Allison charming, humble, and entertaining: the venerable doctor is also an accomplished blues harmonica player. Director Bill Haney weaves Allison's personal story with the medical case of Sharon Belvin, a patient diagnosed with melanoma in 2004 who soon enrolled in Allison's clinical trials. Belvin has since been entirely cancer-free, according to press materials.

"We are facing a global health challenge that knows no boundaries or race or religion, and we are all relying on gifted and passionate scientists and healthcare workers to contain and ultimately beat this thing," said Haney, in a statement. "Jim Allison and the unrelenting scientists like him are my heroes – and I'll bet they become yours!"

Jim Allison: Breakthrough premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App.

------

This article originally ran on CultureMap.
Jim Allison's groundbreaking work with T cells helped him net the award. Photo courtesy of MD Anderson Cancer Center

Houston scientist wins Nobel Prize for breakthrough cancer treatment

Research Recognition

A University of Texas MD Anderson Cancer Center scientist has been lauded for his cancer research. Jim Allison, Ph.D., was announced as the recipient of the 2018 Nobel Prize in Physiology or Medicine on October 1.

Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform, is the first MD Anderson scientist to receive the world's most coveted award for discoveries in the fields of life sciences and medicine. Allison won for his work in launching an effective new way to attack cancer by treating the immune system rather than the tumor, according to a release.

"I'm honored and humbled to receive this prestigious recognition," Allison says in a statement. "A driving motivation for scientists is simply to push the frontiers of knowledge. I didn't set out to study cancer, but to understand the biology of T cells, these incredible cells to travel our bodies and work to protect us."

Allison shares the award with Tasuku Honjo, M.D., Ph.D., of Kyoto University in Japan. When announcing the honor, the Nobel Assembly of Karolinska Institute in Stockholm noted in a statement that "stimulating the ability of our immune system to attack tumor cells, this year's Nobel Prize laureates have established an entirely new principle for cancer therapy."

The prize recognizes Allison's basic science discoveries on the biology of T cells, the adaptive immune system's soldiers, and his invention of immune checkpoint blockade to treat cancer. According to MD Anderson, Allison's crucial insight was to block a protein on T cells that acts as a brake on their activation, freeing the T cells to attack cancer. He developed an antibody to block the checkpoint protein CTLA-4 and demonstrated the success of the approach in experimental models.

Allison's work led to the development of the first immune checkpoint inhibitor drug which would become the first to extend the survival of patients with late-stage melanoma. Follow-up studies show 20 percent of those treated live for at least three years, with many living for 10 years and beyond, unprecedented results, according to the cancer center.

"Jim Allison's accomplishments on behalf of patients cannot be overstated," says MD Anderson president Peter WT Pisters, M.D., in a statement. "His research has led to life-saving treatments for people who otherwise would have little hope. The significance of immunotherapy as a form of cancer treatment will be felt for generations to come."

"I never dreamed my research would take the direction it has," Allison adds. "It's a great, emotional privilege to meet cancer patients who've been successfully treated with immune checkpoint blockade. They are living proof of the power of basic science, of following our urge to learn and to understand how things work."

---

This story originally appeared on CultureMap.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston SaaS startup closes $12M series A funding round with support from local VC

money moves

A Houston startup with a software-as-a-service platform for the energy transition has announced it closed a funding round with participation from a local venture capital.

Molecule closed its $12 million series A, and Houston-based Mercury Fund was among the company's investors. The company has a cloud-based energy trading and risk management solution for the energy industry and supports power, natural gas, crude/refined products, chemicals, agricultural commodities, softs, metals, cryptocurrencies, and more.

"We led the seed round of Molecule upon their formation and are excited to participate in their series A," says Blair Garrou, co-founder and managing director of Mercury, in a news release. "Molecule's success in the ETRM/CTRM industry, especially in relation to electricity and renewables, positions them as the company to beat for the energy transition in the 2020s."

The company will use its new funds to further build out its product as well as introduce offerings to manage renewables credits, according to the release.

"In 2020, we realized that electricity — the growth commodity of the 2020s — represented over half of Molecule's customer base, and we decided to double down," says Sameer Soleja, founder and CEO of Molecule, in the release. "We were also rated the No. 1 SaaS ETRM/CTRM vendor. With this fundraise, we have the fuel to become No. 1 SaaS platform for power and renewables, and then the market leader overall.

"Molecule is ready to power the energy transition," Soleja continues.

Molecule's last round of funding closed in November 2014. The $1.1 million seed round was supported by Mercury Fund and the Houston Angel Network.

Houston-based afterlife planning startup launches new app

there's an app for that

The passing of a loved one is followed with grief — and paperwork. A Houston company that's simplifying the process of afterlife planning and decision making is making things even easier with a new smartphone app.

The Postage, a digital platform meant to ease with affair planning, recently launched a mobile app to make the service more accessible following a particularly deadly year. The United States recorded 3.2 million fatalities — the most deaths in its history, largely due to the coronavirus pandemic.

After losing three family members back-to-back, Emily Cisek dealt first hand with the difficulty of wrapping up a loved one's life. She saw how afterlife planning interrupted her family's grieving and caused deep frustration. Soon, she began to envision a solution to help people have a plan and walk through the process of losing someone.

The Postage, which launched in September, provides a platform for people to plan their affairs and leave behind wishes for loved ones. The website includes document storage and organization, password management, funeral and last wishes planning, and the option to create afterlife messages to posthumously share with loved ones.

"Right now, as it stands ahead of this app, end-of-life planning is really challenging. It's this daunting thing you have to sit down and do at your computer," says Cisek. Not only is it "daunting," but it's time-consuming. According to The Postage, families can expect to spend nearly 500 hours on completing end-of-life details if there is no planning done in advance.

With more than 74 percent of The Postage's web traffic coming from mobile users, an app was a natural progression. In fact, Entrepreneur reports the average person will spend nine years on their mobile device. Cisek wanted to meet users where they are at with a user-friendly app that includes the same features as the desktop website.

"What we wanted to do [with the app] is make it so easy to plan your life and the end of your life using one click — as easy as it was for posting and commenting on social media," explains Cisek. "People are so used to reflecting on those behaviors and clicking one button to add a picture ... we wanted to make it that simple," she continued.

Cisek and her team focused on providing a "seamless experience" within the app, which took approximately four months to build, which mirrors the desktop platform.

Though The Postage's website had mobile functionality, the app includes the ability to record and upload content. Whether snapping a picture of their insurance policy or recording a video to share with loved ones, The Postage app allows users to capture photos and videos directly within the app.

After snapping a picture, "the next step inherently is sharing it with your loved ones," says Cisek. Photos, family recipes and videos can easily be shared securely with loved ones who accept your invitation to The Postage so "that legacy continues on," she says.

Since The Postage's fall launch, the company has grown a steady base of paid subscribers with plans to expand.

"We're really starting to change the way people plan for the future," says Cisek.

5 most popular innovation stories in Houston this week

WHAT'S TRENDING

Editor's note: Another week has come and gone, and it's time to round up the top headlines from the past few days. Trending Houston tech and startup news on InnovationMap included innovators to know, events not to miss this month, big winners at Rice University, and more.

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Daniel Powell of Spark Biomedical, Carrie Colbert of Curate Capital, and Carson Hager of SafeFun. Courtesy photos

In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — venture capital, medical devices, and software — recently making headlines in Houston innovation. Continue reading.

10+ can't-miss Houston business and innovation events online in May

Don't miss these informative online events happening throughout the month of May. Photo by Getty Images

This month, Houstonians have yet another good batch of online innovation events — from Zoom panels to virtual conferences — and you and your tech network need to know about them.

Here's a roundup of virtual events not to miss this month — like Houston Tech Rodeo, a virtual showcase from Rice University's data science students, and more. Continue reading.

Report: Houston ranks among the worst cities for unnecessary medical treatments

Houston hospitals have been reported to have an excess of unnecessary health care tests and procedures. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston boasts of being home to the Texas Medical Center, the world's biggest medical complex. Yet Houston's medical community also holds a distinction that's hardly boast-worthy: It's the worst major metro area in Texas for unnecessary health care tests and procedures.

A study released May 4 by the Lown Institute, a health care think tank, shows hospitals in the Houston area collectively fare worse than their counterparts in Dallas-Fort Worth, San Antonio, and Austin for overuse of tests and procedures that the institute says offer little to no benefit. Continue reading.

Rice University student startups win $65,000 in competition

The annual H. Albert Napier Rice Launch Challenge awarded equity-free cash prizes to three impressive student startups. Photo courtesy of Rice University

A Rice University startup competition concluded with a big win for a company started by students trying to use tech to help prevent veteran suicide.

The startup, rutd: resources united. technology driven., a secure platform that can deliver more than 14,000 mental health resources to veterans, won first prize at the virtually held H. Albert Napier Rice Launch Challenge last week. The prize included a $27,500 check. Continue reading.

Houston expert: Telework in research might be here to stay

The telework paradigm may be here to stay in research long after the COVID pandemic tapers off. Graphic by Miguel Tovar/University of Houston

How many of the research administrator's duties can be done from home? COVID-19 is showing us emphatically that the answer is many.

There are some aspects that take a little bit of inventive scheduling to make happen, but overall, the telework paradigm may be here to stay in research long after the COVID pandemic tapers off. Continue reading.

View All Listings